- Tytuł:
- p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
- Autorzy:
- Źródło:
- Oncogene [Oncogene] 2010 Jul 08; Vol. 29 (27), pp. 3942-52. Date of Electronic Publication: 2010 May 10.
- Typ publikacji:
- Journal Article; Research Support, Non-U.S. Gov't
- MeSH Terms:
-
Cyclin-Dependent Kinase Inhibitor p21/*metabolism
Down-Regulation/*drug effects
Forkhead Transcription Factors/*metabolism
Histone Deacetylase Inhibitors/*pharmacology
Neoplasms/*pathologyPaired Box Transcription Factors /*metabolism
Transcriptional Activation/*drug effects
Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cyclin-Dependent Kinase Inhibitor p21/genetics ; Drug Synergism ; Early Growth Response Protein 1/metabolism ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Genotype ; Histone Deacetylase Inhibitors/administration & dosage ; Histone Deacetylase Inhibitors/therapeutic use ; Humans ; Mice ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/metabolism ; Rhabdomyosarcoma, Alveolar/drug therapy ; Rhabdomyosarcoma, Alveolar/genetics ; Rhabdomyosarcoma, Alveolar/metabolism ; Rhabdomyosarcoma, Alveolar/pathology ; Staurosporine/administration & dosage ; Staurosporine/analogs & derivatives ; Staurosporine/pharmacology ; Staurosporine/therapeutic use ; Valproic Acid/administration & dosage ; Valproic Acid/pharmacology ; Valproic Acid/therapeutic use ; Xenograft Model Antitumor Assays
Czasopismo naukowe